# Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Gabapentin From Nerpentin 600 mg (Test ) F.C.T (Aman Pharma ,Egypt.) and Gabapentin From Neurontin 300 mg (Referance ) H.G.C. ( Pfizer Egypt)

> **NCT04805827** · NA · COMPLETED · sponsor: **Pharma Guide CRO** · enrollment: 34 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Gabapentin
- **DRUG:** Neurontin

## Key facts

- **NCT ID:** NCT04805827
- **Lead sponsor:** Pharma Guide CRO
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-25
- **Primary completion:** 2021-03-07
- **Final completion:** 2021-03-07
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2021-09-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04805827

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04805827, "Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Gabapentin From Nerpentin 600 mg (Test ) F.C.T (Aman Pharma ,Egypt.) and Gabapentin From Neurontin 300 mg (Referance ) H.G.C. ( Pfizer Egypt)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04805827. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*